ARTHROPLASTY
Floseal hemostatic agent reduces blood loss but not transfusion needs in TKA patients
J Arthroplasty. 2014 Oct;29(10):1950-5.108 patients undergoing unilateral primary total knee arthroplasty were randomly allocated to either receive a thrombin-based topical hemostatic matrix or to a control group who did not receive the hemostatic agent. The study sought to determine the effects of the hemostatic sealant on inblood loss, as well as the need for transfusion. Results revealed the mean blood loss, drain output and length of stay were significantly favored the hemostatic matrix group over the control group. There was no significant difference found in transfusion requirements and mean hemoglobin loss between groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
